- Home
- BIAF vs KTTA Comparison
BIAF vs KTTA Comparison
Compare BIAF & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | KTTA |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 5.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BIAF | KTTA |
|---|---|---|
| Price | $1.63 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 99.0K | ★ 21.5M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,776,739.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.25 | $0.28 |
| 52 Week High | $46.53 | $3.85 |
Technical Indicators
Market Signals| Indicator | BIAF | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 60.15 |
| Support Level | $1.34 | $1.11 |
| Resistance Level | $1.79 | $1.33 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 74.09 | 47.72 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).